Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate-Reference-Cited by-同舟云学术

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate

Published:2019-07-15 Issue:9 Volume:33 Page:1455-1465
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Gupta Samir K.,Post Frank A.,Arribas José R.,Eron Joseph J.,Wohl David A.,Clarke Amanda E.,Sax Paul E.,Stellbrink Hans-Jürgen,Esser Stefan,Pozniak Anton L.,Podzamczer Daniel,Waters Laura,Orkin Chloe,Rockstroh Jürgen K.,Mudrikova Tatiana,Negredo Eugenia,Elion Richard A.,Guo Susan,Zhong Lijie,Carter Christoph,Martin Hal,Brainard Diana,SenGupta Devi,Das Moupali

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference36 articles.

1. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years;Nelson;AIDS,2007

2. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate;Hamzah;J Infect,2017

3. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study;Sax;J Acquir Immune Defic Syndr,2014

4. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence;Hall;Am J Kidney Dis,2011

5. Mechanism of active renal tubular efflux of tenofovir;Ray;Antimicrob Agents Chemother,2006

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-10-01

2. HIV-associated kidney disease: the changing spectrum and treatment priorities;Current Opinion in Nephrology & Hypertension;2024-08-20

3. Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis;Expert Opinion on Drug Safety;2024-08-19

4. Three Year Outcomes after Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti;2024-08-14

5. Role of the pharmacist caring for people at risk of or living with HIV in Canada;Canadian Pharmacists Journal / Revue des Pharmaciens du Canada;2024-08-02